Lu AG13909
Alternative Names: Lu-AG13909Latest Information Update: 27 Oct 2025
At a glance
- Originator Lundbeck A/S
- Class Monoclonal antibodies
- Mechanism of Action Corticotropin receptor antagonists
-
Orphan Drug Status
Yes - Congenital adrenal hyperplasia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pituitary ACTH hypersecretion
- Phase I/II Congenital adrenal hyperplasia
Most Recent Events
- 12 Jul 2025 Pharmacodynamics and adverse events data from a phase I/II trial in Congenital adrenal hyperplasia presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)
- 12 Jul 2025 Pharmacodynamics and adverse events data from a phase I/II trial in Congenital adrenal hyperplasia presented at the 107th Annual Meeting of the Endocrine Society (ENDO-2025)
- 20 Jun 2025 Lu AG13909 receives Orphan Drug status for Congenital adrenal hyperplasia in European Union